|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Mr. Paul Hudson||CEO & Director||5.63M||N/D||1967|
|Mr. Jean-Baptiste Chasseloup de Chatillon||Exec. VP & CFO||N/D||N/D||1965|
|Mr. Laurent Gilhodes||Principal Accounting Officer and VP of Corp. Accounting||N/D||N/D||N/D|
|Mr. Bruno MÃ©nard||Chief Information officer||N/D||N/D||N/D|
|Dr. Josephine Fubara||Chief Science Officer of Consumer Health Care||N/D||N/D||N/D|
|Mr. George Grofik C.F.A., CPA, CFA||Head of Investor Relations||N/D||N/D||N/D|
|Ms. Karen Linehan||Exec. VP of Legal Affairs & Gen. Counsel||N/D||N/D||1959|
|Mr. Dante Beccaria||Global Compliance Officer & VP||N/D||N/D||N/D|
|Mr. Josep Catlla||Head of Communications||N/D||N/D||N/D|
|Mr. Pierre Chancel||Sr. VP of Global Diabetes and Sr. VP of Global Marketing||N/D||N/D||1957|
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
La calificación ISS Governance QuickScore de Sanofi a partir del 1 de abril de 2021 es 5. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 4; Compensación: 7.